Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLYTE vs TERIPARATIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Treatment of postmenopausal women with osteoporosis at high risk for fracture,Treatment of men with primary or hypogonadal osteoporosis at high risk for fracture,Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
20 mcg subcutaneously once daily.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Terminal half-life approximately 1 hour following subcutaneous administration; clinical duration limited by rapid clearance, necessitating once-daily dosing.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Teriparatide is metabolized via non-specific proteolytic degradation in the liver and peripheral tissues. No specific cytochrome P450 enzymes are involved.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Primarily hepatic metabolism via nonspecific proteolytic enzymes; no significant renal or biliary excretion; minimal unchanged drug in urine or feces.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Approximately 40-50% bound to plasma proteins, primarily albumin.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Approximately 0.2-0.3 L/kg, indicating distribution largely confined to extracellular fluid and bone.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Subcutaneous: approximately 95% bioavailability.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not recommended in severe renal impairment (Cr Cl ≤30 m L/min) due to lack of data.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C).
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
No dose adjustment required; clinical studies included patients >65 years with no significant differences in efficacy or safety.
None
Increased risk of osteosarcoma in animal studies. Avoid use in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior radiation therapy involving the skeleton, or bone metastases.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Risk of osteosarcoma (see black box warning),Orthostatic hypotension may occur, especially with initial doses,Hypercalcemia may occur; monitor serum calcium,Use with caution in patients with active urolithiasis,May increase serum uric acid
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Paget's disease of bone,Unexplained elevations of alkaline phosphatase,Open epiphyses (pediatric patients),Prior radiation therapy involving the skeleton,Bone metastases or history of skeletal malignancies,Metabolic bone diseases other than osteoporosis,Pregnancy and lactation,Hypersensitivity to teriparatide or any component
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
No specific food interactions. However, ensure adequate dietary calcium and vitamin D intake (e.g., dairy products, green leafy vegetables, fortified foods) to support the anabolic effect. Avoid excessive sodium, protein, and caffeine, which may increase calcium excretion. Do not take calcium supplements within 2 hours of teriparatide injection if instructed to take them separately, though generally they can be taken together.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal skeletal effects.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No human data; teriparatide likely excreted in milk in low amounts. M/P ratio unknown. Recommend caution or avoid breastfeeding.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
No dose adjustment recommended based on pharmacokinetic changes; however, use only if potential benefit justifies risk.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Teriparatide is a recombinant human parathyroid hormone analog used for osteoporosis. It is the only anabolic agent that stimulates new bone formation. Administer as a subcutaneous injection in the thigh or abdomen. Rotate injection sites. Do not use in patients with Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or bone metastases. Maximum duration of therapy is 24 months over a patient's lifetime due to an increased risk of osteosarcoma in rats. Monitor serum calcium levels at baseline and periodically; may cause transient hypercalcemia 4-6 hours after dosing. Contraindicated in hypercalcemia, pregnancy, and lactation.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
Store teriparatide in the refrigerator at 2-8°C (36-46°F) and never freeze. Protect from light and do not use if the solution is cloudy, colored, or contains particles.,Inject once daily using the provided pen device. Administer at the same time each day, preferably in the morning, into the thigh or abdomen. Rotate injection sites to avoid lipodystrophy.,Sit or lie down during the first few doses if you experience dizziness or rapid heartbeat, as teriparatide may cause orthostatic hypotension. Stand up slowly.,Do not use teriparatide for more than 24 months total over your lifetime. Inform your doctor if you have Paget's disease, a history of radiation therapy, or bone cancer.,Contact your doctor if you have persistent nausea, vomiting, constipation, muscle weakness, or confusion, as these may be signs of hypercalcemia.,Take calcium and vitamin D supplements as recommended by your doctor, typically 1000 mg calcium and 800 IU vitamin D daily, to support bone formation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLYTE vs TERIPARATIDE, answered by our medical review team.
COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. TERIPARATIDE is a Parathyroid Hormone Analog that works by Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLYTE and TERIPARATIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. The standard adult dose of TERIPARATIDE is: 20 mcg subcutaneously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLYTE and TERIPARATIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. TERIPARATIDE is classified as Category A/B. Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal ske. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.